Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjectpatientcancercellcells
  Phrases that lowered it: myelomavisitplasmathe studyprostate
• Sponsor's past termination rate: 44.4% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 27.0% (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 35 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Keywords listed: 6 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: not given (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 92.0% (raises risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 3883 (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma NCT01160484 · started 2009 · scored riskier than 73% of active trials completed
• Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma NCT00843310 · started 2008 · scored riskier than 96% of active trials terminated
• Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma NCT02441686 · started 2015 · scored riskier than 53% of active trials completed
• Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L NCT00807599 · started 2008 · scored riskier than 36% of active trials completed
• Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma NCT00689936 · started 2008 · scored riskier than 58% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.